Qu Yuan, Liu Hui-Ying, Guo Xiao-Xi, Luo Yan, Wang Cheng-Xiao, He Jiang-Hua, Xu Tian-Rui, Yang Ye, Cui Xiu-Ming
Yunnan Provincial Key Laboratory of Panax notoginseng, Key Laboratory of Panax notoginseng Resources Sustainable Development and Utilization of State Administration of Traditional Chinese Medicine, University Based Provincial Key Laboratory of Screening and Utilization of Targeted Drugs, Faculty of Life Science and Technology, Kunming University of Science and Technology No. 727 South Jingming Rd., Chenggong District Kunming 650500 China
College of Materials and Chemical Engineering, Chongqing University of Arts and Science Chongqing 402160 China.
RSC Adv. 2018 Dec 4;8(70):40471-40482. doi: 10.1039/c8ra08021f. eCollection 2018 Nov 28.
A microwave processing technology was applied to degrade saponins from the stems and leaves of . Six transformation products (1-6), named 20()-ginsenoside Rg (1), 20()-ginsenoside Rg (2), notoginsenoside SFt (3), ginsenoside Rk (4), ginsenoside Rg (5), and 20()-ginsenoside Rh (6) were isolated and identified from a microwave processed extract of the stems and leaves of (MEL). This transformation method was also applied for producing the minor ginsenosides in flowers, seeds and pedicels of . The extract and compounds 1-6 in MEL were evaluated for anticancer and anticoagulant activities. The results showed that the MEL extract and transformation products had outstanding inhibitory activities against human cervical cancer Hela and lung cancer A549 cells. The strongest inhibitory effect was observed for 20()-Rh (6) with an IC value of 8.23 μM in Hela cells. Moreover, the results showed that the MEL significantly prolonged prothrombin time in a concentration-dependent manner. The anticoagulant effect of the MEL improved with the increased contents of Rk, Rg, and SFt.
一种微波处理技术被应用于降解[植物名称]茎和叶中的皂苷。从[植物名称]茎和叶的微波处理提取物(MEL)中分离并鉴定出六种转化产物(1 - 6),分别命名为20(S)-人参皂苷Rg₃(1)、20(R)-人参皂苷Rg₃(2)、三七皂苷SF₁(3)、人参皂苷Rk₃(4)、人参皂苷Rg₅(5)和20(S)-人参皂苷Rh₂(6)。这种转化方法也被应用于制备[植物名称]花、种子和花梗中的次要人参皂苷。对MEL中的提取物和化合物1 - 6进行了抗癌和抗凝活性评估。结果表明,MEL提取物和转化产物对人宫颈癌Hela细胞和肺癌A549细胞具有显著的抑制活性。在Hela细胞中,观察到20(S)-Rh₂(6)的抑制作用最强,IC₅₀值为8.23 μM。此外,结果表明,MEL以浓度依赖的方式显著延长凝血酶原时间。MEL的抗凝作用随着Rk₃、Rg₅和SF₁含量的增加而增强。